☰

April D. Lake, Ph.D. - Publications

Affiliations: 
2013 Pharmacology & Toxicology University of Arizona, Tucson, AZ 
Area:
Toxicology, Pharmacology, Molecular Biology, Pathology
Tree Info Grants Similar researchers PubMed Report error

20 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Lake AD, Hardwick RN, Leamon CP, Low PS, Cherrington NJ. Folate receptor-beta expression as a diagnostic target in human & rodent nonalcoholic steatohepatitis. Toxicology and Applied Pharmacology. PMID 30794826 DOI: 10.1016/J.Taap.2019.02.009  0.797
2017 Han J, Dzierlenga AL, Lu Z, Billheimer DD, Torabzadeh E, Lake AD, Li H, Novak P, Shipkova P, Aranibar N, Robertson D, Reily MD, Lehman-McKeeman LD, Cherrington NJ. Metabolomic profiling distinction of human nonalcoholic fatty liver disease progression from a common rat model. Obesity (Silver Spring, Md.). PMID 28452429 DOI: 10.1002/Oby.21855  0.731
2017 Clarke JD, Novak P, Lake AD, Hardwick RN, Cherrington NJ. Impaired N-linked Glycosylation of Uptake and Efflux Transporters in Human Nonalcoholic Fatty Liver Disease. Liver International : Official Journal of the International Association For the Study of the Liver. PMID 28097795 DOI: 10.1111/Liv.13362  0.823
2016 Lake AD, Chaput AL, Novak P, Cherrington NJ, Smith CL. Transcription factor binding site enrichment analysis predicts drivers of altered gene expression in nonalcoholic steatohepatitis. Biochemical Pharmacology. PMID 27836672 DOI: 10.1016/J.Bcp.2016.11.006  0.659
2015 Lake AD, Wood CE, Bhat VS, Chorley BN, Carswell GK, Sey YM, Kenyon EM, Padnos B, Moore TM, Tennant AH, Schmid JE, George BJ, Ross DG, Hughes MF, Corton JC, et al. Dose and Effect Thresholds for Early Key Events in a PPARα-Mediated Mode of Action. Toxicological Sciences : An Official Journal of the Society of Toxicology. PMID 26519955 DOI: 10.1093/toxsci/kfv236  0.332
2015 Lake AD, Novak P, Shipkova P, Aranibar N, Robertson DG, Reily MD, Lehman-McKeeman LD, Vaillancourt RR, Cherrington NJ. Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease. Amino Acids. 47: 603-15. PMID 25534430 DOI: 10.1007/S00726-014-1894-9  0.713
2015 Canet MJ, Hardwick RN, Lake AD, Dzierlenga AL, Clarke JD, Goedken MJ, Cherrington NJ. Renal xenobiotic transporter expression is altered in multiple experimental models of nonalcoholic steatohepatitis. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 43: 266-72. PMID 25488932 DOI: 10.1124/Dmd.114.060574  0.797
2014 Hardwick RN, Clarke JD, Lake AD, Canet MJ, Anumol T, Street SM, Merrell MD, Goedken MJ, Snyder SA, Cherrington NJ. Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis. Toxicological Sciences : An Official Journal of the Society of Toxicology. 142: 45-55. PMID 25080921 DOI: 10.1093/Toxsci/Kfu156  0.747
2014 Clarke JD, Hardwick RN, Lake AD, Lickteig AJ, Goedken MJ, Klaassen CD, Cherrington NJ. Synergistic interaction between genetics and disease on pravastatin disposition. Journal of Hepatology. 61: 139-47. PMID 24613363 DOI: 10.1016/J.Jhep.2014.02.021  0.781
2014 Clarke JD, Hardwick RN, Lake AD, Canet MJ, Cherrington NJ. Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression. The Journal of Pharmacology and Experimental Therapeutics. 348: 452-8. PMID 24403518 DOI: 10.1124/Jpet.113.211284  0.814
2014 Canet MJ, Hardwick RN, Lake AD, Dzierlenga AL, Clarke JD, Cherrington NJ. Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 42: 586-95. PMID 24384915 DOI: 10.1124/Dmd.113.055996  0.794
2014 Clarke JD, Sharapova T, Lake AD, Blomme E, Maher J, Cherrington NJ. Circulating microRNA 122 in the methionine and choline-deficient mouse model of non-alcoholic steatohepatitis. Journal of Applied Toxicology : Jat. 34: 726-32. PMID 24217942 DOI: 10.1002/Jat.2960  0.662
2014 Lake AD, Novak P, Hardwick RN, Flores-Keown B, Zhao F, Klimecki WT, Cherrington NJ. The adaptive endoplasmic reticulum stress response to lipotoxicity in progressive human nonalcoholic fatty liver disease. Toxicological Sciences : An Official Journal of the Society of Toxicology. 137: 26-35. PMID 24097666 DOI: 10.1093/Toxsci/Kft230  0.793
2014 Clarke JD, Novak P, Lake AD, Shipkova P, Aranibar N, Robertson D, Severson PL, Reily MD, Futscher BW, Lehman-McKeeman LD, Cherrington NJ. Characterization of hepatocellular carcinoma related genes and metabolites in human nonalcoholic fatty liver disease. Digestive Diseases and Sciences. 59: 365-74. PMID 24048683 DOI: 10.1007/S10620-013-2873-9  0.647
2013 Bodeman CE, Dzierlenga AL, Tally CM, Mulligan RM, Lake AD, Cherrington NJ, McKarns SC. Differential regulation of hepatic organic cation transporter 1, organic anion-transporting polypeptide 1a4, bile-salt export pump, and multidrug resistance-associated protein 2 transporter expression in lymphocyte-deficient mice associates with interleukin-6 production. The Journal of Pharmacology and Experimental Therapeutics. 347: 136-44. PMID 23929842 DOI: 10.1124/Jpet.113.205369  0.646
2013 Lake AD, Novak P, Shipkova P, Aranibar N, Robertson D, Reily MD, Lu Z, Lehman-McKeeman LD, Cherrington NJ. Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease. Toxicology and Applied Pharmacology. 268: 132-40. PMID 23391614 DOI: 10.1016/J.Taap.2013.01.022  0.746
2013 Hardwick RN, Ferreira DW, More VR, Lake AD, Lu Z, Manautou JE, Slitt AL, Cherrington NJ. Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 554-61. PMID 23223517 DOI: 10.1124/Dmd.112.048439  0.818
2012 Canet MJ, Hardwick RN, Lake AD, Kopplin MJ, Scheffer GL, Klimecki WT, Gandolfi AJ, Cherrington NJ. Altered arsenic disposition in experimental nonalcoholic fatty liver disease. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 1817-24. PMID 22699396 DOI: 10.1124/Dmd.112.046177  0.803
2011 Lake AD, Novak P, Fisher CD, Jackson JP, Hardwick RN, Billheimer DD, Klimecki WT, Cherrington NJ. Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 39: 1954-60. PMID 21737566 DOI: 10.1124/Dmd.111.040592  0.809
2010 Hardwick RN, Fisher CD, Canet MJ, Lake AD, Cherrington NJ. Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 38: 2293-301. PMID 20805291 DOI: 10.1124/Dmd.110.035006  0.757
Show low-probability matches.